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Pseudomonas aeruginosa
To construct a conjuga-ve plasmid with 
CRISPR/Cas9 technology and another one used as 
nega-ve control
To validate the constructed 
plasmid’s ability to conjugate 
and re-sensi-ze
To validate the constructed 
system to limit HGT
To assess in vivo the 
conjuga-ve CRISPR/Cas9 
system ac-vity
A single conjuga-ve plasmid with CRISPR/Cas9 system could be used as a strategy to cure an-bio-c resistance plasmids and prevent their acquisi-on in P. aeruginosa.
REFERENCES
o It will be demonstrated if pCRISPR-Conj is able to conjugate and cure an7bio7c resistance
plasmids in vitro and in vivoà ~90% of curing efficiency
o It will be shown whether pCRISPR-Conj limits HGTà 100-500-fold reduc7on in conjuga7on
frequency
o Future applica7ons of the constructed system:
• Reduce therapy’s limita1on and prolong the
effec1ve lifespan of conven1onal an1bio1cs
• Cut down the exposure of pa1ents to an1bio1cs
• It would not be necessary to look into new
an1bio1cs
• Reduce an1bio1c resistant P. aeruginosa in the
human skin microbiota and in water-reservoirs
• Decrease the amount of an1bio1c resistant P.
aeruginosa from water-reservoirs
EXPECTED RESULTS DISSEMINATION PLAN
o Publica7on of the methodology and results in renowned scien-fic
journals related to gene-c engineering, medical research and
an-microbial resistances
















































o One of the most common bacteria related to nosocomial infections
o Worldwide public health threat due to the appearance of antibiotic
resistances
o Intrinsic, adaptive and acquired mechanisms that confer resistances
o Acquisition of antibiotic resistance genes via horizontal gene transfer




Fig. 1. Schema(c representa(on of CRISPR/Cas9
technology.
o Adap7ve immune system of prokaryotes
o 2 main components:
• Cas9 à Endonuclease
• Single guide RNA (sgRNA) à Fusion of
trans-ac-va-ng crRNA and CRISPR RNA
o Poten-al tool to cure an7bio7c resistance plasmids
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Diges7on of the 
assembled product and 
RK2 plasmid, which acts 
as backbone, and liga-on 
1.G. 
4. In vivo assessment
Fig. 2. Scheme of the procedure to
























Gibson Assembly of the 
overlapping fragments previously 
obtained
Individual amplifica-ons of 
J23119 promoters, sgRNAs with 
Csy4 sites, csy4 and cas9 by PCR













Iden7fica7on of the target sequences 
with PAM located downstream
Synthesis of target sequences with complementary 
overhangs to sticky ends of pSQT1313 







pCas9, which will 
be used as nega-ve 
control
1.F. 
Fig. 3. Representa(on of plasmid
curing assay with the conjuga(ve
CRISPR/Cas9 system.
blaVIM-1
Fig. 4. Scheme of HGT
limita(on assay.
Fig. 5. Representation
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